Legend Biotech Corp
LEGN42.287USD
+0.697+1.67%
Market hours （ET）Quotes delayed by 15 min
7.78BMarket Cap
LossP/E TTM
More Details of Legend Biotech Corp Company
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Company Info
Ticker SymbolLEGN
Company nameLegend Biotech Corp
IPO dateJun 04, 2020
Founded at2015
CEODr. Ying Huang, Ph.D.
Number of employees2600
Security typeDepository Receipt
Fiscal year-endJun 04
Address2101 Cottontail Lane
CitySOMERSET
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code08873
Phone17328505598
Websitehttps://investors.legendbiotech.com/
Ticker SymbolLEGN
IPO dateJun 04, 2020
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-100.00%
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
--
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
--
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Ms. Jessie Yeung
Ms. Jessie Yeung
Interim Chief Financial Officer, Director
Interim Chief Financial Officer, Director
--
--
Dr. Peter Salovey, Ph.D.
Dr. Peter Salovey, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
168.29M
86.28%
Europe
26.67M
13.67%
China
90.00K
0.05%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Jul 18
Updated: Fri, Jul 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
6.11%
Westfield Capital Management Company, L.P.
3.75%
T. Rowe Price Associates, Inc.
3.65%
HHLR Advisors, Ltd.
3.25%
Suvretta Capital Management, LLC
2.03%
Other
81.21%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
6.11%
Westfield Capital Management Company, L.P.
3.75%
T. Rowe Price Associates, Inc.
3.65%
HHLR Advisors, Ltd.
3.25%
Suvretta Capital Management, LLC
2.03%
Other
81.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor
18.95%
Investment Advisor/Hedge Fund
18.32%
Hedge Fund
8.47%
Research Firm
1.51%
Corporation
1.22%
Venture Capital
0.50%
Bank and Trust
0.40%
Pension Fund
0.13%
Insurance Company
0.09%
Other
50.41%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
544
92.22M
50.04%
-25.07M
2025Q1
566
91.15M
49.68%
-26.78M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
2023Q2
459
88.99M
49.23%
+9.84M
2023Q1
421
72.14M
43.70%
-3.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
11.26M
6.11%
-452.89K
-3.87%
Mar 31, 2025
Westfield Capital Management Company, L.P.
6.92M
3.75%
+1.20M
+21.07%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.73M
3.65%
-78.41K
-1.15%
Mar 31, 2025
HHLR Advisors, Ltd.
5.98M
3.25%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
3.75M
2.03%
+253.73K
+7.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
1.69%
-148.24K
-4.55%
Mar 31, 2025
Braidwell LP
2.98M
1.62%
--
--
Mar 31, 2025
Invesco Advisers, Inc.
2.91M
1.58%
-373.35K
-11.36%
Mar 31, 2025
MFS Investment Management
2.27M
1.23%
+5.83K
+0.26%
Mar 31, 2025
Genscript Biotech Corp
2.25M
1.22%
--
--
Dec 31, 2024
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Harbor Health Care ETF
6.68%
Matthews Emerging Markets Discovery Active ETF
4.54%
Matthews Emerging Markets Sustainable Future Active ETF
4.48%
Global X Genomics & Biotechnology ETF
3.6%
Tema Oncology ETF
2.35%
Virtus LifeSci Biotech Products ETF
1.86%
KraneShares MSCI All China Health Care Index ETF
1.31%
iShares Biotechnology ETF
0.39%
ProShares Ultra Nasdaq Biotechnology
0.33%
iShares MSCI Emerging Markets Min Vol Factor ETF
0.29%
View more
Harbor Health Care ETF
Proportion6.68%
Matthews Emerging Markets Discovery Active ETF
Proportion4.54%
Matthews Emerging Markets Sustainable Future Active ETF
Proportion4.48%
Global X Genomics & Biotechnology ETF
Proportion3.6%
Tema Oncology ETF
Proportion2.35%
Virtus LifeSci Biotech Products ETF
Proportion1.86%
KraneShares MSCI All China Health Care Index ETF
Proportion1.31%
iShares Biotechnology ETF
Proportion0.39%
ProShares Ultra Nasdaq Biotechnology
Proportion0.33%
iShares MSCI Emerging Markets Min Vol Factor ETF
Proportion0.29%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
